Namodenoson (CF102)

About Can Fite Biopharma

Can Fite Biopharma's mission is to develop and commercialize novel, orally available therapeutics targeting the A3 adenosine receptor for oncology, inflammatory, and metabolic diseases. Its key achievements include establishing a robust pipeline with multiple Phase II/III candidates, securing significant out-licensing partnerships for its lead assets across major markets in Asia, Europe, and North America, and generating clinical proof-of-concept for its platform. The company's strategy is to advance its most promising programs through late-stage trials to achieve regulatory milestones, while continuing to monetize its pipeline through regional partnerships and non-dilutive funding to drive towards commercialization.

About Can Fite Biopharma

Can Fite Biopharma's mission is to develop and commercialize novel, orally available therapeutics targeting the A3 adenosine receptor for oncology, inflammatory, and metabolic diseases. Its key achievements include establishing a robust pipeline with multiple Phase II/III candidates, securing significant out-licensing partnerships for its lead assets across major markets in Asia, Europe, and North America, and generating clinical proof-of-concept for its platform. The company's strategy is to advance its most promising programs through late-stage trials to achieve regulatory milestones, while continuing to monetize its pipeline through regional partnerships and non-dilutive funding to drive towards commercialization.

Therapeutic Areas

Other Hepatocellular Carcinoma Drugs